Brief introduction of company honors
-Selected for guidance and authorization from the Taiwan Institute of Economics, Science and Technology
-Specializes in "pharmaceutical expertise, cell preparation process planning, genetic and protein engineering, molecular virology, clinical medical and experimental research, and immune research" and innovates and maintains a high degree of competitiveness, commending companies with outstanding business results.
-Won the honor of one of the top ten outstanding enterprises in biotechnology.
-A leading company in regenerative 、immune cell therapy and personalized medical application platforms.
-Products: Research, development and clinical application of NK/NKT/CIK and Car NK immunity, mesenchymal stem cells and exosome preparations.

Brief introduction of company honors
Precision Biotech Taiwan Corp. has won the ward for its powerful team lineup, excellent operating quality and outstanding clinical effect.
· It is recognized for continuous innovation of R&D, more accurate and effective drug-cell combination therapy and patented technology for developing cryopreservation of immune cell products. · In 2021 and 2022, it passed the approval of residence in Hong Kong Science & Technology Parks and Taipei Bioinnovation Park respectively.
· It has built cell preparation plants which comply with PIC/S Guide to GMP in Taiwan and Hangzhou to produce cells in Asia Pacific region.
· Phase I/IIa clinical trial was conducted in Taiwan and phase I/II cell therapy clinical trials was conducted in mainland China.
· By cooperating with domestic and foreign countries, it has developed a new generation of immune cell technology (CAR-NK), contributed to the health and development of cancer patients, and won the Taiwan Innovation Award in the Startup Company Category.

Brief introduction of company honors
· This product won the award for its innovative process, high-efficiency allogeneic culture method and patented formula.
· It outputs highly active allogeneic immune cell products against cancer, which can effectively amplify NK/NKT up to 10000 times.
· The test result for killing cancer cells is over 80%.
· By culturing immune cells from healthy donors ex vivo, phase I clinical trial has been 100% safe and achieved the expected therapeutic effectiveness.
· It provides more effective and safer immunotherapy products for cancer patients with solid tumors.

Brief introduction of company honors
Won the highest honor of Innovation Gold Medal Award of Taipei Biotech Awards.
·The first allogeneic immune cell technology in Taiwan has passed the approval of phase I/IIa TFDA/IND clinical trial.
· With its own patented technology, NK/NKT cell culture techniques, it is no longer bound by foreign countries: screening cells without magnetic beads, special cell technology, and continuous innovation and improvement.
· The price of mass production of 98 ~ 99% NK/NKT cells with optimization technology is competitive.
·Quality control of GMP or clinical grade of all materials.
·With cryopreservation technology of immune cells, it will expand the generalizability of ready-touse market. ·Combined with immune cell cryopreservation technology, it will expand the application of ready-to-use markets.
·Non-serum culture-low risk of infection. The patented culture medium serves as exclusive supplier for the future market of cell therapy

Corporate Honors Summary
Received the highest honor of Taiwan's quality SNQ seal
NK/NKT live cells with a high survival rate of 95%
Safe and Burden free: Japan has been using it for more than 20 years, and the Ministry of Health and Welfare has evaluated and announced its highly efficient cell killing ability: cancer cell killing effect E: T5:1>76%. High concentration of active ingredients: over 99% NK/NKT, possessing both NK and NKT cell characteristics.
The new combination therapy has significant therapeutic effects: it can be combined with other anticancer drugs in the early stage for more effective treatment (it has been approved for eight solid cancers in the first phase of clinical trial and special management application with the affiliated hospitals of Taipei Medical College and Hualien Tzu Chi Hospital, respectively). Currently, it has been approved for 12 cancer types.
NK live cells with a high purity of 99% and a survival rate of over 95%.